Drug Profile
Autoimmune disease therapy - Hadassah Medical Organization/Harvard Medical School
Alternative Names: Anti-CD3+glycolipidLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Hadassah Medical Organization; Harvard Medical School
- Class Glycolipids; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders in Israel (PO)
- 26 Apr 2009 Pharmacodynamics data from a preclinical trial in Hepatitis presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
- 31 Jan 2008 Phase-I clinical trials in Autoimmune disorders in Israel (PO)